secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106545
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema Q2 net loss $43.8M, selects 90 mg palazestrant dose for Phase 3 trials, cash $361.9M
--------------------------------------------------------------------------------

- Q2 net loss $43.8M vs $30.4M YoY; increase driven by $10M Aurigene milestone and higher R&D for late-stage trials.
- Selected 90 mg once-daily palazestrant for OPERA-01 Part 2 and OPERA-02 frontline combo trial with ribociclib.
- OPERA-01 top-line data expected H2 2026; OPERA-02 initiation on track for Q3 2025.
- Cash, equivalents, and marketable securities $361.9M as of June 30, 2025.
- Mature palazestrant+ribociclib Phase 1b/2 data to be presented at ESMO 2025; OP-3136 Phase 1 enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017025106545/0000950170-25-106545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017025106545/olma-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer